Matrix metalloproteinase-3 in myasthenia gravis compared to other neurological disorders and healthy controls

Steven P Luckman1, Nils Erik Gilhus, Fredrik Romi

  • 1Section for Neurology, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.

Autoimmune Diseases
|August 10, 2011
PubMed

Insights

Matrix metalloproteinase-3 (MMP-3) is elevated in myasthenia gravis (MG) patients, suggesting a specific role in this autoimmune neuromuscular disorder. MMP-3 levels were significantly higher in MG compared to multiple sclerosis and stroke patients.

Area of Science:

  • Neurology
  • Immunology
  • Biochemistry

Background:

  • Matrix metalloproteinase-3 (MMP-3) degrades proteins like agrin, crucial for neuromuscular signaling and acetylcholine receptor clustering.
  • Elevated MMP-3 levels have been observed in some myasthenia gravis (MG) patients.
  • A pathogenic role for MMP-3 in neurological disorders is suspected but not confirmed.

Purpose of the Study:

  • To investigate and compare MMP-3 levels in myasthenia gravis (MG) patients versus other neurological conditions and healthy controls.
  • To determine if MMP-3 has a specific association with MG pathogenesis.

Main Methods:

  • Quantified MMP-3 levels in 124 MG patients, 59 multiple sclerosis (MS) patients, 74 epilepsy patients, 33 acute stroke patients, and 90 healthy controls.
  • Defined MMP-3 positivity as concentrations above 48 ng/mL.
  • Compared mean MMP-3 concentrations across all study groups.

Main Results:

  • 15.3% of MG patients were MMP-3 positive with a mean concentration of 79.9 ng/mL.
  • MMP-3 positivity was significantly lower in MS (3.4%), epilepsy (6.7%), stroke (0%), and control (4.4%) groups.
  • Mean MMP-3 concentration in MG patients (25.5 ng/mL) was significantly higher than in MS (16.6 ng/mL) and stroke (11.7 ng/mL) groups.

Conclusions:

  • MMP-3 may play a specific pathogenic role in myasthenia gravis.
  • Elevated MMP-3 levels in MG suggest a potential link beyond general autoimmune disease association.
  • Further research is warranted to elucidate MMP-3's precise function in MG.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...